tbuckley/cabot-search huggingface dataset:
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
Authors: Jose M. Pacheco, Lauren Averett Byers
Journal: Cancer Discovery (2019)

Abstract Summary: Effective options are limited for patients with small-cell lung cancer who develop progressive disease during or after etoposide plus platinum-based therapy. In this issue of Cancer Discovery, Farago and colleagues highlight the data for temozolomide plus olaparib in this patient population and demonstrate the potential to accelerate biomarker discovery through co-clinical trials utilizing patient-derived xenografts. See related article by Farago et al., p. 1372.
A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Authors: D.P. Petrylak, U.N. Vaishampayan, K.R. Patel, C.S. Higano, C. Albany, N.A. Dawson, B.A. Mehlhaff, D.I. Quinn, L.T. Nordquist, V.J. Wagner, J. Shen, L. Trandafir, O. Sartor
Journal: Annals of Oncology (2019)
Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Authors: A. Mafficini, C. Cantù, D. Antonello, M. Simbolo, L. Piredda, V. Lever, B. Rusev, S. Pecori, M. Milella, R.T. Lawlor, A. Scarpa
Journal: Annals of Oncology (2019)
Abstract 105: Optimal Timing of Endotracheal Intubation Improves Survival in Out-of-Hospital-Cardiac Arrest Resuscitation
Authors: Anuar Turgulov, Steve Lin, Jason E Buick, Gerald Kierzek, Cathy C Zhan, Laurie J Morrison, Valeria E Rac
Journal: Circulation (2011)

INTRODUCTION: Endotracheal intubation in out-of-hospital cardiac arrest (OHCA) patients remains controversial. Prehospital intubation may have detrimental effects on patient outcomes; however, the ...
Frequency and Clinical Characteristics Associated with Putative CAR Targets ADGRE2, CCR1, CD70, and LILRB2 in Acute Myeloid Leukemia
Authors: Rabia Shahswar, Arnold Kloos, Razif Gabdoulline, Sagarajit Mohanty, Christian Koenecke, Martin Wichmann, Blerina Neziri, Piroska Klement, Johannes Schiller, Sabrina Klesse, Alessandro Liebich, Courteney Lai, Jürgen Krauter, Arne Trummer, Walter Fiedler, Hartmut Kirchner, Gerhard Heil, Zhixiong Li, Lothar Hambach, Arnold Ganser, Felicitas Thol, Michael Heuser
Journal: Blood (2018)
Disturbed NK Cell Compartment In Human CML and Bcr-Abl Positive Mice.
Authors: Christiane I-U Chen, Steffen Koschmieder, Linda Kamp, Bianca Altvater, Sibylle Pscherer, Holden Maecker, Wolfgang E. Berdel, Heribert Juergens, Peter P Lee, Claudia Rossig
Journal: Blood (2010)
Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center
Authors: B. Grana Suarez, A. Molina, J. Mosquera, A. Martinez, M. Lado, M. Forjan, R. Liste, C. Reboredo, I. Gomez-Randulfe, P. Cordeiro, O. Coroas, M. Deben
Journal: Annals of Oncology (2019)
Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Authors: N. Halama, U. Prüfer, A. Froemming, D. Beyer, D. Eulberg, J.U. Jungnelius, A. Mangasarian
Journal: Annals of Oncology (2019)
Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines
Authors: David J. Seastone, Aziz Nazha, Priyanka A Pophali, Moshe C. Ornstein, Hetty E. Carraway, Anjali S. Advani, Aaron T. Gerds, Matt E. Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres
Journal: Blood (2014)
Prehabilitation can be tricky or empowering
Authors: Dave deBronkart
Journal: BMJ (2019)

I hope we can consider prehabilitation in every possible domain.1 My wife and I have experienced its benefits and the effects of its absence.

When she experienced successful bilateral knee replacements, prehabilitation was part of the plan and undoubtedly helped her rapid recovery.2 But when she had foot surgery, the surgeon had no interest in anything …
A blinded comparison of patient treatments to therapeutic options presented by an artificial intelligence-based clinical decision-support system
Authors: S. Suwanvecho, H. Suwanrusme, T. Jirakulaporn, N. Taechakraichana, P. Lungchukiet, N. Thanakarn, W. Decha, W. Boonpakdee, A. Preininger, I. Dankwa-Mullan, M. Solomon, S. Wang, G. Jackson, V. Patel, E.H. Shortliffe, N. Kiatikajornthada
Journal: Annals of Oncology (2019)
Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation
Authors: Wandi Zhu, Andrea Mazzanti, Taylor L. Voelker, Panpan Hou, Jonathan D. Moreno, Paweorn Angsutararux, Kristen M. Naegle, Silvia G. Priori, Jonathan R. Silva
Journal: Circulation Research (2018)

Rationale: Mutations in the SCN5A gene, encoding the α subunit of the Nav1.5 channel, cause a life-threatening form of cardiac arrhythmia, long QT syndrome type 3 (LQT3). Mexiletine, which is structurally related to the Na + channel-blocking anesthetic lidocaine, is used to treat LQT3 patients. However, the patient response is variable, depending on the genetic mutation in SCN5A . Objective: The goal of this study is to understand the molecular basis of patients’ variable responses and build a predictive statistical model that can be used to personalize mexiletine treatment based on patient’s genetic variant. Methods and Results: We monitored the cardiac Na + channel voltage-sensing domain (VSD) conformational dynamics simultaneously with other gating properties for the LQT3 variants. To systematically identify the relationship between mexiletine block and channel biophysical properties, we used a system-based statistical modeling approach to connect the multivariate properties to patient phenotype. We found that mexiletine altered the conformation of the Domain III VSD, which is the same VSD that many tested LQT3 mutations affect. Analysis of 15 LQT3 variants showed a strong correlation between the activation of the Domain III-VSD and the strength of the inhibition of the channel by mexiletine. Based on this improved molecular-level understanding, we generated a systems-based model based on a dataset of 32 LQT3 patients, which then successfully predicted the response of 7 out of 8 patients to mexiletine in a blinded, retrospective trial. Conclusions: Our results imply that the modulated receptor theory of local anesthetic action, which confines local anesthetic binding effects to the channel pore, should be revised to include drug interaction with the Domain III-VSD. Using an algorithm that incorporates this mode of action, we can predict patient-specific responses to mexiletine, improving therapeutic decision making.
Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients
Authors: Anthony R. Mato, Nicole Lamanna, Chaitra S. Ujjani, Danielle M. Brander, Brian T. Hill, Christina Howlett, Alan P Skarbnik, Bruce Cheson, Clive S Zent, Jeffrey J Pu, Pavel Kiselev, Spencer Henick Bachow, Allison M Winter, Allan-Louie Cruz, David F. Claxton, Catherine Daniel, Krista Isaack, Kaitlin H Kennard, Colleen Timlin, Melissa Yacur, Molly Fanning, Lauren E. Strelec, Daniel J. Landsburg, Sunita Dwivedy Nasta, Stephen J. Schuster, David L Porter, Chadi Nabhan, Paul Barr
Journal: Blood (2016)
Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
Authors: E. Martinelli, T. Troiani, C. Cardone, D. Ciardiello, N. Zanaletti, C. Borrelli, M. Terminiello, A. Avallone, A. Falcone, E. Maiello, R. Bordonaro, D. Santini, C. Garufi, F. Pietrantonio, C. Pinto, G. Santabarbara, N. Normanno, F. Ciardiello
Journal: Annals of Oncology (2019)
Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumours treated with immune checkpoint inhibitors (ICIs)
Authors: L. Ghiglione, C Cabrera Galvez, O. Reig, A. Soler-Perromat, J.C. Soler-Perromat, M. Sánchez, A. Arcocha, N. Viñolas, A. Prat, B. Mellado, N. Reguart
Journal: Annals of Oncology (2019)
Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response
Authors: M. Cobo Dols, M.D.C. Beato Zambrano, L. Cabezón Gutiérrez, R. Chicas Sett, I. Blancas, F.J. García Navalón, J.L. Firvida Pérez, G. Serrano Bermúdez, P. Togores Torres, I. Delgado Mingorance, A. Giraldo Marín, A. Librán Oriol, A. Paredes Lario, P. Sánchez Mauriño, O. Higuera Gomez, D. Moreno Muñoz, A.J. Jiménez López, I. Huerta González, A. Sanz Yagüe, B. Soler López
Journal: Annals of Oncology (2019)
5-year adherence to adjuvant endocrine therapy among women with breast cancer: A nationwide study using group-based trajectory modeling
Authors: V. Memoli, G. Lailler, C Le Bihan-Bejamin, M.K. Bendiane, S. Lauzier, J. Mancini, P.-J. Bousquet, A.-D. Bouhnik
Journal: Annals of Oncology (2019)
Efficacy of olanzapine combination in prevention of nausea &amp; vomiting in highly emetogenic chemotherapy
Authors: S.C. Saldanha, L. Dasappa, L.A. Jacob, S.M. Babu, K.N. Lokesh, A.H. Rudresha, R.K. Lakkavalli, J. Kumar
Journal: Annals of Oncology (2019)
Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk
Authors: Rebecca D. Kehm, Jeanine M. Genkinger, Robert J. MacInnis, Esther M. John, Kelly-Anne Phillips, Gillian S. Dite, Roger L. Milne, Nur Zeinomar, Yuyan Liao, Julia A. Knight, Melissa C. Southey, Wendy K. Chung, Graham G. Giles, Sue-Anne McLachlan, Kristen D. Whitaker, Michael Friedlander, Prue C. Weideman, Gord Glendon, Stephanie Nesci, kConFab Investigators, Irene L. Andrulis, Saundra S. Buys, Mary B. Daly, John L. Hopper, Mary Beth Terry
Journal: Cancer Research (2019)

Although physical activity is associated with lower breast cancer risk for average-risk women, it is not known if this association applies to women at high familial/genetic risk. We examined the association of recreational physical activity (self-reported by questionnaire) with breast cancer risk using the Prospective Family Study Cohort, which is enriched with women who have a breast cancer family history (
Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, &amp; MSI-H cohorts
Authors: H.J. Conter, L.D. MacDonald, S. Fiset, Y.M. Bramhecha, M. Chaney, G.N. Rosu
Journal: Annals of Oncology (2019)
儿童 DLE 的基于实践的差异
Authors: L. Arkin, K. Buhr, H. Brandling‐Bennett, Y. Chiu, B. Chong, M. Curran, R. Hunt, A.S. Paller, V. Werth, M. Klein‐Gitelman, E. Scheven, K. Ardalan
Journal: British Journal of Dermatology (2019)

术语“红斑狼疮”指的是一系列相关疾病。盘状红斑狼疮 (DLE) 是一种在儿童中罕见的皮肤红斑狼疮。其可导致毁容性瘢痕。某些患者出现系统性红斑狼疮 (SLE),这是一种影响全身的红斑狼疮,其可导致多器官损害。多项小型研究表明,25 ‐ 30% 的 DLE 儿童患者随时间推移出现 SLE,但与此相关的风险因素尚不明确。SLE 早期诊断和治疗很有帮助。本研究采用一种调查方法来比较美国和加拿大两个医学专业(学术型风湿科医师和皮肤科医师)为 DLE 儿童患者提供护理的实践模式。本研究的目的在于识别两组间的一致方面,以及基于实践的差异。若两个专业达到 70% 或更多的一致,则出现共识(一致)。作者发现了应在所有儿童诊断为 DLE 时查看某些实验室研究的共识。两组都同意,存在“除 ANA 以外的其他自身抗体”、关节炎或肾炎是 SLE 的高风险特性,对此应增加系统性疾病的筛查。没有其他一致同意的 SLE 风险因素,包括先前在 DLE 成人患者中显示的风险因素。两组都同意,泛发性 DLE 的一线系统性疗法(全身治疗)应为羟氯喹。作者未就哪些药物可用于治疗耐药性皮肤病达成一致。总而言之,本研究发现某些一致方面,但许多方面存在基于实践的差异。需要有关 DLE 儿童患者的更多数据来确定最佳实践方法。作者正在开展一项回顾性队列研究,该研究可能有助于填补这一空白。
Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumours leading to tumour inhibition and memory responses
Authors: S. Martomo, X.-J. Feng, D. Lu, Z. Polonskaya, X. Luna, M.V. Poyurovsky, K. McCracken, F. Miyara, L. Li, S. Aggarwal, J. Patel
Journal: Annals of Oncology (2019)
A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy
Authors: M.H. Chen, Y. Chao, L. Tenner, N.A. Hung, D. Cutler, D. Kramer, M-F R Kwan, C.-T. Hung
Journal: Annals of Oncology (2019)
Polyarteritis Nodosa With Reversible FDG Accumulation in Vessels and Kidneys
Authors: Nanami Mino, Hiroyuki Yamashita, Yuko Takahashi, Hiroshi Kaneko
Journal: Clinical Nuclear Medicine (2019)

Abstract A 59-year-old man presented with fever and lower extremity myalgia. Laboratory studies revealed elevated C-reactive protein. 18 F-FDG PET/CT demonstrated FDG uptake not only in the brachial arteries, femoral arteries, and their main ramifications, which were equivalent to small- to medium-sized arteries but also in the kidneys. Angiography revealed a renal aneurysm, confirming the diagnosis of polyarteritis nodosa. The increased FDG uptake in the vessels and kidneys resolved after 6 months of glucocorticoid treatment.
LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling
Authors: Tingting Tang, Changying Guo, Tiansong Xia, Rui Zhang, Ke Zen, Yi Pan, Liang Jin
Journal: Theranostics (2019)

Background: Breast cancer stem cells (BCSCs) play an essential role in facilitating breast cancer relapse and metastasis. The underlying mechanism, however, remains incompletely understood. In the current study, we investigated the clinical significance, biological function and mechanism of a long noncoding RNA CCAT1 (LncCCAT1) in BCSCs. Methods: Firstly, lncRNAs expression in poorly differentiated breast cancer tissues and BCSCs were measured by lncRNA microarray and confirmed in breast cancer tissues and cell lines. The functional roles and mechanisms of LncCCAT1 were further investigated by gain and loss of function assays in vitro and in vivo. Results: LncCCAT1 is markedly upregulated in breast cancer tissues BCSCs and is correlated with poor outcomes in breast cancer patients. Overexpression of LncCCAT1 contributes to the proliferation, stemness, migration and invasion capacities of BCSCs. Mechanistic investigation suggests that LncCCAT1 can interact with miR-204/211, miR-148a/152 and Annexin A2(ANXA2), then upregulate T-cell factor 4 (TCF4) or promote translocation of β-catenin to the nucleus where it activates TCF4, leading to the activation of wingless/integrated (Wnt) signaling. Furthermore, TCF4 can also bind to the promoter of LncCCAT1 to promote LncCCAT1 transcription, thus forming a positive feedback regulatory circuit of LncCCAT1-TCF4-LncCCAT1 in BCSCs. Conclusions: LncCCAT1 plays an important role in breast cancer progression and may serve as a novel target for breast cancer diagnosis and therapy.
Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
Authors: D. Daniel, V. Kuchava, I. Bondarenko, O. Ivashchuk, D. Spigel, A. Dasgupta, S. Reddy, T. Melkadze, J. Jaal, I. Kudaba, L. Hart, A. Matitashvili, K.D. Koynov, Z. Yang, S.G. Wolfe, R. Malik, S.R. Morris, J.M. Antal, J. Goldschmidt
Journal: Annals of Oncology (2019)
Clinical factors for predicting clinical responses to methotrexate
Authors: K.X. Yan, Y.J. Zhang, L. Han, Q. Huang, Z.H. Zhang, X. Fang, Z.Z. Zheng, N. Yawalkar, Y.L. Chang, Q. Zhang, L. Jin, D.F. Qian, X.Y. Li, M.S. Wu, Q.H. Xu, X.J. Zhang, J.H. Xu
Journal: British Journal of Dermatology (2019)

Psoriasis is a persistent disease that causes inflammation throughout the body and affects approximately 1% to 3% of the world population. It generally appears as red scaly patches and papules over several areas of the skin. Methotrexate is an effective medication for the treatment of psoriasis; however, it is not widely used because its efficacy is unpredictable. This study aimed to determine whether clinical factors of psoriasis and the genes that make people more susceptible to it may affect the effectiveness of methotrexate. The authors identified 221 Chinese patients with psoriasis who were treated with methotrexate for 12 weeks. The patients were divided into the responder and non-responder groups, based on whether their psoriasis improved (responded) after the 12-weeks treatment. The responder group comprised patients with more than 75% improvement while the non-responder group comprised those with less than 50% improvement in psoriasis. Associations between 18 common variations of 14 genes that make people susceptible to psoriasis (LCE3D, IL12B, NFKB1A, TNIP1, ERAP1, ZNF683, MTHFR, AIM2, PTTG1, GJB2, SYNE2, IKZF3, SERPINB8, ZNF816A) and the HLA-Cw6 status were analysed, based on their response to methotrexate. The differences between the clinical factors of methotrexate responders and non-responders were compared. Body mass index, arthritis, and rs10036748 genotype were significantly associated with the patients’ response to methotrexate. The authors concluded that patients with psoriasis and the TT genotype of rs10036748 on the TNIP1 gene, those with lower body mass indices, and those without arthritis will respond better to methotrexate.
A Breath of Fresh Air: Opening up the Lung Cancer Genome
Authors: Anne M. Bowcock
Journal: Cancer Research (2019)

Abstract In this issue of Cancer Research, Wang and colleagues identify a large number of regulatory sites within the genomes of non–small cell lung cancers with a global scan for open chromatin (assaying for transposase-accessible chromatin with sequencing). They show that this type of profiling might substitute RNA sequencing in classifying lung cancer samples and in making predictions about prognosis. They also show experimentally that genome editing of some regulatory sites upregulates the expression of GSTM1 and GSTT1, which are required for detoxification of carcinogens and whose low expression levels are associated with lung cancer risk. See related article by Wang et al., p. 4840
Correction: Characterizing the Epidemiological Transition in Mexico: National and Subnational Burden of Diseases, Injuries, and Risk Factors
Authors: Gretchen Stevens, Rodrigo H Dias, Kevin J. A Thomas, Juan A Rivera, Natalie Carvalho, Simón Barquera, Kenneth Hill, Majid Ezzati
Journal: PLoS Medicine (2008)

In the key to Figure 5, the Diarrhea (Diar) and Respiratory Infections (Resp) labels on the key were reversed.The corrected Figure 5 follows.
PavordS and HuntB, The Obstetric Hematology Manual, 2nd EdnCambridge University Press, Cambridge, 2018
Authors: Barbara J. Bain
Journal: American Journal of Hematology (2019)

With hematology becoming increasingly complex and specialized, there is an increasing role for books such as this, that deal with one part of the specialty in depth and are cross-disciplinary in their approach. There are 50 authors, drawn from hematology, blood transfusion, obstetrics, anesthesia, and radiology. The book is scholarly and authoritative but at the same time practical. It will be welcomed by hematologists and obstetricians alike. Themes covered include the management during pregnancy of hematinic deficiency anemias, and sickle cell disease, thalassemia, and other inherited red cell disorders. Thrombosis and hemostasis are dealt with in great detail – the physiological changes in coagulation during pregnancy, inherited coagulation defects, thrombophilia, management of thromboembolism, prosthetic heart valves, anticoagulant therapy and obstetric hemorrhage. There are chapters on the important themes of pre-eclampsia and thrombotic microangiopathies and on the, fortunately uncommon, occurrences of hematological neoplasms during pregnancy. The late effects of chemoradiotherapy and how they may be prevented or ameliorated are discussed. The fetus is specifically dealt with in chapters on red cell and platelet alloimmunisation, and on prenatal diagnosis and management of congenital bleeding disorders. A particularly useful feature is the use of illustrative case reports at the conclusion of each chapter, including occasional examples of “What can go wrong?” Despite being published by Cambridge University Press, part of the University of Cambridge, the book is published in American English, which should appeal to American readers. Could anything be improved? In the thalassemia chapter, I would have liked a clear discussion of the use of iron-chelating therapy during the first trimester of pregnancy and during breast-feeding. Proof reading was not always rigorous; in one chapter headings of tables are attached to the wrong tables; in another, two “color” figures are in black, white and gray. However, these are minor imperfections. This comprehensive book will be of considerable value to those working in this field and is strongly recommended.
NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Authors: C. Thibault, F. Audenet, D. Borchiellini, O. Huillard, P. Barthelemy, D. Pouessel, A. Flechon, H. Blons, C. Sautès-Fridman, C.-M. Sun, V. Verkarre, N. Pallet, A. Mejean, M. Rouabah, I. Helali, R.-T. Elaidi, S. Oudard
Journal: Annals of Oncology (2019)
Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Authors: D.C. Guven, O.H. Aktepe, Z. Berk, G. Guner, H. Taban, B.Y. Aktas, Z.C. Duran, S. Akin, Z. Arik, N. Kertmen, S. Kilickap, A. Turker, O. Dizdar
Journal: Annals of Oncology (2019)
IDRiD: Diabetic Retinopathy – Segmentation and Grading Challenge
Authors: Prasanna Porwal, Samiksha Pachade, Manesh Kokare, Girish Deshmukh, Jaemin Son, Woong Bae, Lihong Liu, Jianzong Wang, Xinhui Liu, Liangxin Gao, TianBo Wu, Jing Xiao, Fengyan Wang, Baocai Yin, Yunzhi Wang, Gopichandh Danala, Linsheng He, Yoon Ho Choi, Yeong Chan Lee, Sang-Hyuk Jung, Zhongyu Li, Xiaodan Sui, Junyan Wu, Xiaolong Li, Ting Zhou, Janos Toth, Agnes Baran, Avinash Kori, Sai Saketh Chennamsetty, Mohammed Safwan, Varghese Alex, Xingzheng Lyu, Li Cheng, Qinhao Chu, Pengcheng Li, Xin Ji, Sanyuan Zhang, Yaxin Shen, Ling Dai, Oindrila Saha, Rachana Sathish, Tânia Melo, Teresa Araújo, Balazs Harangi, Bin Sheng, Ruogu Fang, Debdoot Sheet, Andras Hajdu, Yuanjie Zheng, Ana Maria Mendonça, Shaoting Zhang, Aurélio Campilho, Bin Zheng, Dinggang Shen, Luca Giancardo, Gwenolé Quellec, Fabrice Mériaudeau
Journal: Medical Image Analysis (2019)
Waste in the US Health Care System
Authors: Howard Bauchner, Phil B. Fontanarosa
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS)
Authors: V.E. Pacheco-Barcia, R. Mondejar, O. Martinez-Saez, F Longo Munoz, J A Moreno Monteagudo, J. Rogado, O. Donnay, C. Santander, A Carrato Mena, R Colomer Bosch
Journal: Annals of Oncology (2019)